is generally believed that immunosuppresion enhances viral replication with consequent increase in hepatocyte infection. Withdrawal of cytotoxic or immunosuppressive drugs Hepatitis B reactivation following chemotherapy withdrawal may result in hepatitis, hepatic failure and leads to restoration of immune function, resulting in rapid destruction of infected hepatocytes. This may give rise to death. We studied the clinical outcome and the causes of hepatic events of hepatitis B surface antigen positive a clinical picture of hepatitis and even hepatic failure and death. 6 Bone marrow transplantation (BMT) has become a recipients undergoing bone marrow transplantation. Twenty-four hepatitis B surface antigen patients were standard treatment for various hematological malignancies.
Summary:
is generally believed that immunosuppresion enhances viral replication with consequent increase in hepatocyte infection. Withdrawal of cytotoxic or immunosuppressive drugs Hepatitis B reactivation following chemotherapy withdrawal may result in hepatitis, hepatic failure and leads to restoration of immune function, resulting in rapid destruction of infected hepatocytes. This may give rise to death. We studied the clinical outcome and the causes of hepatic events of hepatitis B surface antigen positive a clinical picture of hepatitis and even hepatic failure and death. 6 Bone marrow transplantation (BMT) has become a recipients undergoing bone marrow transplantation. Twenty-four hepatitis B surface antigen patients were standard treatment for various hematological malignancies.
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During the procedure, intensive chemotherapy with and matched with 24 hepatitis B surface antigen negative patients for age, sex, CMV positive serology, underlying without total body irradiation was required to ablate the recipients' marrow. Furthermore, immunosuppressive hematological disease and type of bone marrow transplantation. Post-BMT, there were 18 patients in the agents have to be administered for at least 6 months after BMT for prevention or treatment of graft-versus-host dishepatitis B surface antigen positive group and four patients in the hepatitis B surface antigen negative ease (GVHD). Therefore, one would anticipate that chemotherapy withdrawal HBV reactivation would be a problem group who suffered from hepatitis (P Ͻ 0.05). Thirteen of the 18 hepatitis were related to HBV reactivation in after bone marrow transplantation. In fact, fatal fulminant hepatitis due to HBV reactivation has been reported in the hepatitis B surface antigen positive group and none of the four hepatitis in the hepatitis B surface antigen HBsAg positive carriers undergoing BMT. 8 The aim of this study was to define the incidence of hepatic events negative group (P = 0.01). The hepatitis B surface antigen positive group also had an increased incidence of (hepatitis and hepatic failure) in the HBsAg positive patients undergoing BMT and the causes of the hepatic acute graft-versus-host disease of liver (6 vs 1, P = 0.03). However, there was no significant increase in the incievents. dence of veno-occlusive disease (10 vs 7, P = 0.40) and persistent hepatitis (3 vs 0, P = 0.07) in the hepatitis B Patients and methods surface antigen positive group. Using the log-rank test, there was no significant difference in survival between
Patients studied the hepatitis B surface antigen positive and negative recipients.
Two hundred and twenty-four patients received a BMT at Keywords: HBV; bone marrow transplantation; hepatitis;
Queen Mary Hospital between May 1990 and March 1995. VOD; GVHD; HBV reactivation All of them were screened before BMT for hepatitis serology (HBsAg/Ab, HBeAg/Ab, anti-HCV (EIA II), anti-HDV). Twenty-five patients were HBsAg positive and among them one was also HCV Ab positive (EIA II).
Chronic hepatitis B infection is endemic in Hong Kong
Twenty-four patients who were HBsAg positive alone with a carrier rate of 10%.
1 Previously, we reported a (HBeAg positive/anti-HBe positive/HBV DNA positive: higher incidence of clinical hepatitis in lymphoma patients 11/13/9) were matched with 24 HBsAg negative (anti-HBs undergoing chemotherapy who were hepatitis B surface positive/negative: 11/13) and HCV Ab negative patients for antigen (HBsAg) positive than in those who were negaage (30. HBsAg positive group, 15 were transient and three persistent. Of the 15 patients in the HBsAg positive group who suffered from transient hepatitis, there were 11 anicteric and two icteric episodes and two hepatic failures. In the on two consecutive determinations at least 5 days apart.
HBsAg negative group, only four patients suffered from Icteric hepatitis was defined as hepatitis associated with transient hepatitis (all four were anicteric) and none sufclinical jaundice and serum bilirubin level that exceeded 30 fered from persistent hepatitis. There were significantly mol/l (normal, Ͻ19 mol/l). Hepatitis was defined to be more cases of transient hepatitis in the HBsAg positive transient if the duration was less than 6 months and to be group (P = 0.001). The mean onset of transient hepatitis persistent if the duration was more than 6 months. Hepatitis was 120 days in the HBsAg positive group (range: 27-425 would be related to reactivation of HBV if there was an days) and 112 days in the HBsAg negative group (range: accompanying elevation of serum HBV DNA Ͼ2 × of the pre-exacerbation baseline, or the serum HBV DNA turned from negative to positive with exacerbation of the hepatitis. ations.
11-236 days) after BMT (P = NS). HBV reactivation was tation, conditioning regimen, presence or absence of HBeAg, HBeAb and serum HBV DNA prior to BMT considered to be the cause of hepatitis in 13 of the 18 hepatitis in the HBsAg positive group and none of the four cases (Table 4) . in the HBsAg negative group (P = 0.01). Among the 15 cases of transient hepatitis in the HBsAg positive group, 10 Survival (67.7%) were attributed to HBV reactivation, two (13.3%) related to relapse of the underlying hematological maligThere were eight deaths in the HBsAg positive group and six deaths in the HBsAg negative group (P = NS). The nancy and one (6.7%) to systemic sepsis. The cause in the remaining two was indeterminate. In the HBsAg negative causes of death (HBsAg positive/HBsAg negative) were disease relapse (4/3), fungal infection (1/3) and hepatic failgroup, no cases of hepatitis were related to HBV (HBsAg, HBeAg, HBV DNA negative). Two were caused by sysure (3/0). Using the log-rank test, there were no significant differences in survival between HBsAg positive and temic sepsis and the other two were indeterminate (Table  3) . Three patients had persistent hepatitis in the HBsAg HBsAg negative groups (P = 0.54) (Figure 1 ). positive group and none in the HBsAg negative group (P = 0.07). These three episodes were all related to HBV reactivation. Onset of the persistent hepatitis was 130 days Discussion (range: 108-153 days). Two of these patients later died of hepatic failure. Altogether, there were four episodes of hepPreviously, we reported an increased incidence of hepatic events in HBsAg positive patients (21-67%) undergoing atic failure in the HBsAg positive group and none in the HBsAg negative recipients (P = 0.04). All four episodes of chemotherapy for lymphoma. 2, 3 In this retrospective study, we report an increased incidence of hepatitis in HBsAg hepatic failure, including three deaths, were related to HBV reactivation. There were six cases of acute hepatic GVHD positive patients receiving bone marrow transplantation (75%). Of the 18 episodes of hepatitis in these HBsAg posiin the HBsAg positive group and only one in the HBsAg negative group (P = 0.03). Among the six cases of acute tive patients, 13 (72.2%) were related to HBV reactivation. hepatic GVHD in the HBsAg positive group, two were grade one and four were grade two. In the HBsAg negative group, there was only one grade one. However, the differ- Table 4 Comparison of the 24 HBsAg positive patients who did and did not develop hepatitis after BMT ences in the severity of acute GVHD between the HBsAg positive and negative groups did not reach statistical sig- hepatitis was not associated with age, sex, underlying hematological diseases, type of bone marrow transplan- The mean onset of these episodes was around 4 months acute hepatic GVHD and the HBsAg positive status of the recipients was found in this study. Previously, it has been after BMT and this coincides with the time of immune recovery 12 and tailing down of immunosuppression. In the shown that acute GVHD of the liver could be related to HCV and CMV infection. 19, 20 The exact mechanism is HBsAg positive group, there were four episodes of hepatic failure related to HBV reactivation, with three deaths. This unknown. It is possible that viral infection could augment the expression of the minor MHC antigens in the recipients, is significantly higher than in the HBsAg negative group.
Reactivation of hepatitis B virus (HBV) replication is which serve as targets for donor lymphocytes. 21 Also, enhanced cytokines production has been found in patients generally postulated to be related to enhanced viral replication followed by restoration of immune function (on with acute GVHD. 22 It could be that chronic HBV infection increases the production of cytokines and augments the withdrawal of immunosuppression), resulting in rapid destruction of infected hepatocytes. 13 Therefore, the develdevelopment of acute GVHD. To conclude, BMT recipients who were HBsAg positive, opment of hepatitis in these HBsAg positive patients may be prevented, at least theoretically by suppressing viral repas compared to those who were HBsAg negative, had an increased incidence of post-BMT hepatitis, hepatic failure lication during and shortly after the tailing down of immunosuppression. Recently, second generation nucleosand acute hepatic GVHD. However, the overall post-BMT survival was not affected by the HBsAg positive status of ide analogues, such as lamivudine and famciclovir, have been shown in animal models and human studies to be the recipients. effective in inhibiting HBV replication. [14] [15] [16] The effectiveness of these agents in preventing HBV reactivation in Acknowledgements HBsAg positive patients receiving chemotherapy or bone marrow transplantation remains to be assessed.
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ence of HBeAg was associated with the development of hepatitis in HBsAg positive patients following chemotherapy for lymphoma.
2 In this study, we were unable to References identify any factors as associated with the development of hepatitis in the HBsAg patients undergoing bone marrow 
Yeoh EK (eds). Viral Hepatitis Infection in the Western
Also, some other factors, such as pre-BMT liver histology per se could increase the incidence of VOD. In our study, ease of the liver following bone marrow transplantation.
As most of the patients were profoundly thrombocyto- shortcoming into consideration, an association between
